- Home
- EXP vs KYMR Comparison
EXP vs KYMR Comparison
Compare EXP & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXP | KYMR |
|---|---|---|
| Founded | 1963 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.8B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EXP | KYMR |
|---|---|---|
| Price | $186.11 | $78.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 26 |
| Target Price | ★ $226.44 | $108.04 |
| AVG Volume (30 Days) | 406.6K | ★ 699.7K |
| Earning Date | 04-29-2026 | 05-18-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ 1.18 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | ★ $495,023,000.00 | $39,211,000.00 |
| Revenue This Year | $1.84 | $16.05 |
| Revenue Next Year | $1.69 | $4.79 |
| P/E Ratio | $16.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $185.50 | $19.45 |
| 52 Week High | $243.64 | $103.00 |
Technical Indicators
Market Signals| Indicator | EXP | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 41.62 |
| Support Level | N/A | $77.78 |
| Resistance Level | $240.80 | $95.90 |
| Average True Range (ATR) | 7.04 | 4.58 |
| MACD | -3.86 | -1.57 |
| Stochastic Oscillator | 4.38 | 9.76 |
Price Performance
Historical ComparisonAbout EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.